Achieve Life Sciences/ACHV



About Achieve Life Sciences

Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over the counter (OTC) products.





Trading on



Biotechnology & Drugs


Richard Stewart




Seattle, United States

ACHV Metrics

Market cap
P/E ratio
Dividend rate

What the Analysts think about ACHV

Analyst Ratings

Majority rating from 6 analysts.

Price Targets

Average projection from 7 analysts.
354.15% upside
High $30.00
Low $10.00
Current price
Average price target

ACHV Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
Q4 23
QoQ growth
Net income
Profit margin

ACHV Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 17.27%
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events


What’s the current market cap for Achieve Life Sciences stock?

Achieve Life Sciences (ACHV) has a market cap of $150.02M as of April 12, 2024.

What is the P/E ratio for Achieve Life Sciences stock?

The price to earnings (P/E) ratio for Achieve Life Sciences (ACHV) stock is 0 as of April 12, 2024.

Does Achieve Life Sciences stock pay dividends?

No, Achieve Life Sciences (ACHV) stock does not pay dividends to its shareholders as of April 12, 2024.

When is the next Achieve Life Sciences dividend payment date?

Achieve Life Sciences (ACHV) stock does not pay dividends to its shareholders.

What is the beta indicator for Achieve Life Sciences?

Achieve Life Sciences (ACHV) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Achieve Life Sciences stock price target?

The target price for Achieve Life Sciences (ACHV) stock is $19.71, which is 354.15% above the current price of $4.34. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Achieve Life Sciences stock

Buy or sell Achieve Life Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing